Arcutis Appoints Rob Scott, MD to Board of Directors
Key Highlights
- ➤Rob Scott, MD appointed to Arcutis board effective October 23, 2026
- ➤Scott brings over 40 years developing and securing approvals for novel medicines
- ➤ZORYVE has strong adoption, with potential new indications and a novel biologic in pipeline
Expert Statements
Frank Watanabe, President and CEO of Arcutis
“Rob has played a central role in bringing some of the industry’s most important medicines, including dermatology and immunology therapies, to the world, and we are excited to welcome him to our board.”
Frank Watanabe, President and CEO of Arcutis
“Rob’s deep experience taking novel medicines from development through approval will be invaluable as we advance our pipeline and work to bring meaningful innovation to people living with chronic inflammatory skin diseases.”
Rob Scott, MD, Board member of Arcutis
“Arcutis is at an exciting stage of growth, with strong adoption of ZORYVE and a growing pipeline of potential new ZORYVE indications and a novel biologic.”
Rob Scott, MD, Board member of Arcutis
“Individuals with chronic skin diseases still need better treatment options, and I look forward to working with the management team and board to help deliver them.”
WESTLAKE VILLAGE, Calif., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovation in immuno-dermatology, today announced that Rob Scott, MD has been appointed to the Arcutis Board of Directors effective October 23, 2026. Dr. Scott is a global pharma industry leader and pioneer with over 40 years of experience inventing, advancing development for, and securing approvals of novel medicines including multiple blockbusters.
“Rob has played a central role in bringing some of the industry’s most important medicines, including dermatology and immunology therapies, to the world, and we are excited to welcome him to our board,” said Frank Watanabe, president and CEO of Arcutis. “Rob’s deep experience taking novel medicines from development through approval will be invaluable as we advance our pipeline and work to bring meaningful innovation to people living with chronic inflammatory skin diseases.”
Get started
Create a free account to read the full story.